The transaction is expected to be completed in the second quarter of 2026, Adamed said in a statement on Thursday.
Adamed said the acquisition is intended to expand production capacity, diversify manufacturing locations and strengthen supply chain resilience and drug security in Europe, Polish state news agency PAP reported.
“We want to build on what is already there: the people, their knowledge and experience,” said Małgorzata Adamkiewicz, Adamed’s chief executive and co-owner.
"It is a solid production plant with a future," she added.
The company said it would retain the existing workforce and preserve current employment conditions at the facility, which is located in Riells, northeastern Spain.
Under Adamed’s strategy, the Riells plant will become a key part of its international manufacturing network, producing high-volume medicines primarily for European markets.
The company plans to invest in modernising production, infrastructure and logistics at the site.
The Spanish factory will be Adamed’s second manufacturing facility outside Poland. The company has owned a plant in Vietnam since 2017.
Adamed said its medicines are used in more than 80 countries. It operates two production plants in Poland, in Pabianice and Ksawerów near the central city of Łódź, and plans to invest about PLN 300 million (EUR 71 million) by 2030 to build a factory for inhaler drugs.
Over the past five years, Adamed has increased annual production by 75 percent, from 2 billion to 3.5 billion tablets.
With the addition of the Riells facility, the company aims to double output to 7 billion tablets annually by 2029.
Adamed is a family-owned pharmaceutical and biotechnology company with full Polish ownership.
(pm/gs)
Source: PAP